Atara Biotherapeutics (ATRA) Stock Forecast, Price & News

Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

Is Atara Biotherapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Atara Biotherapeutics stock.
View analyst ratings for Atara Biotherapeutics or view top-rated stocks.

When is Atara Biotherapeutics' next earnings date?

Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Atara Biotherapeutics.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) issued its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.11. Atara Biotherapeutics had a negative net margin of 1,451.79% and a negative trailing twelve-month return on equity of 113.94%. During the same quarter last year, the company earned ($0.86) EPS.
View Atara Biotherapeutics' earnings history.

What price target have analysts set for ATRA?

5 brokers have issued 12 month price targets for Atara Biotherapeutics' stock. Their forecasts range from $8.00 to $67.00. On average, they expect Atara Biotherapeutics' stock price to reach $32.67 in the next twelve months. This suggests a possible upside of 533.1% from the stock's current price.
View analysts' price targets for Atara Biotherapeutics or view top-rated stocks among Wall Street analysts.

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the following people:

• Dr. Pascal Touchon D.V.M., Pres, CEO & Director (Age 59, Pay $1.09M)
• Mr. Utpal Koppikar M.B.A., Exec. VP & CFO (Age 51, Pay $655.45k) (LinkedIn Profile)
• Mr. Joseph Newell, Exec. VP (Age 52, Pay $670.38k) (LinkedIn Profile)
• Dr. Kristin Yarema Ph.D., SVP & Chief Commercial Officer (Age 51, Pay $700.67k)
• Dr. Jakob Dupont M.D., Exec. VP and Global Head of R&D (Age 57, Pay $595.87k)
• Ms. Charlene Banard, Chief Technical Officer (Age 59)
• Dr. Anhco Nguyen, Chief Scientific Officer (Age 49)
• Eric Hyllengren, VP of Investor Relations & Fin.
• Mr. K. Amar Murugan, Sr. VP & Gen. Counsel (Age 47) (LinkedIn Profile)
• Kerry Beth Daly, Head of Corp. Communications

What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?

6 employees have rated Atara Biotherapeutics CEO Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among Atara Biotherapeutics' employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Atara Biotherapeutics' key competitors?

Some companies that are related to Atara Biotherapeutics include Relay Therapeutics (RLAY), SpringWorks Therapeutics (SWTX), BioCryst Pharmaceuticals (BCRX), ImmunityBio (IBRX), Vaxcyte (PCVX), Krystal Biotech (KRYS), Valneva (VALN), Vericel (VCEL), Immunocore (IMCR), Exscientia (EXAI), Revolution Medicines (RVMD), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Recursion Pharmaceuticals (RXRX) and Instil Bio (TIL).
View all of ATRA's competitors.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (8.77%), Baupost Group LLC MA (8.70%), BlackRock Inc. (8.35%), Vanguard Group Inc. (7.40%), State Street Corp (6.72%) and Wasatch Advisors Inc. (4.09%). Company insiders that own Atara Biotherapeutics stock include Amar Murugan, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar.
View institutional ownership trends for Atara Biotherapeutics.

Which institutional investors are selling Atara Biotherapeutics stock?

ATRA stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Artal Group S.A., Baupost Group LLC MA, Vanguard Group Inc., Citigroup Inc., PDT Partners LLC, Canada Pension Plan Investment Board, and M28 Capital Management LP. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Amar Murugan, Jakob Dupont, Joe Newell, Matthew K Fust, Pascal Touchon, and Utpal Koppikar.
View insider buying and selling activity for Atara Biotherapeutics or view top insider-selling stocks.

Which institutional investors are buying Atara Biotherapeutics stock?

ATRA stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Wasatch Advisors Inc., Goldman Sachs Group Inc., JPMorgan Chase & Co., Renaissance Technologies LLC, Eminence Capital LP, Ensign Peak Advisors Inc, and Sector Gamma AS.
View insider buying and selling activity for Atara Biotherapeutics or or view top insider-buying stocks.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $5.16.

How much money does Atara Biotherapeutics make?

Atara Biotherapeutics has a market capitalization of $481.97 million and generates $20.34 million in revenue each year. The biotechnology company earns $-340.14 million in net income (profit) each year or ($3.640010) on an earnings per share basis.

How many employees does Atara Biotherapeutics have?

Atara Biotherapeutics employs 578 workers across the globe.

What is Atara Biotherapeutics' official website?

The official website for Atara Biotherapeutics is www.atarabio.com.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 278-8930 or via email at [email protected].